English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

New brand-name pharmaceuticals are projected to cost roughly 6.2% more in the long run, at an estimated cost of $850 million a year for Canadians, if the proposed [Canada–European Union Comprehensive Economic and Trade Agreement][1] (CETA) comes into effect.CETA has been signed, but awaits

Brand-name drug costs expected to rise under CETA